Lutz von Wehren1, Fabian Blanke2, Atanas Todorov1, Patricia Heisterbach1, Jannis Sailer1, Martin Majewski3. 1. Orthopädie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland. 2. Klinik für Sportorthopädie und arthroskopische Chirurgie, Orthopädische Fachkliniken der Hessingstiftung, Hessingstrasse 17, 86199, Augsburg, Germany. 3. Orthopädie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland. martin.majewski@usb.ch.
Abstract
PURPOSE: Rotator cuff tears are one of the most common causes of shoulder malfunction and pain, which lead to a significant reduction in the quality of life. This present study investigated the effects of subacromial platelet-rich plasma injections [i.e. autologous conditioned plasma (ACP) injections] as compared to standard subacromial cortisone injection therapy in 50 patients with partial rotator cuff tears. METHODS: Before injection, and 6 weeks, 12 weeks and 6 months thereafter, the patients were assessed by the Constant-Murley score (CMS), the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), the simple shoulder test (SST) and a pain visual analogue scale (VAS). An MRI was also performed before and 6 months after injection. RESULTS: Both patient groups had statistically significant better shoulder score outcomes over time. ASES, SST and CMS outcomes after 12 versus 6 weeks were better in the ACP group as compared to the cortisone group. VAS, ASES and CMS outcomes after 12 weeks versus baseline in the ACP group were better as compared to the cortisone group. There was a statistically significant difference between ACP group and cortisone group 12 weeks after injection regarding VAS, ASES, SST and CMS in favour of the ACP group. The MRI showed an improvement in grade of tendinopathy in both groups, however, without statistically significant differences between the two groups. CONCLUSION: Compared with cortisone injections, ACP injections show earlier benefit as compared to cortisone injections although a statistically significant difference after 6 months could not be found. Therefore, subacromial ACP injections are a good alternative to subacromial cortisone injections, especially in patients with contraindication to cortisone. LEVEL OF EVIDENCE: Therapeutic study, Level III.
PURPOSE: Rotator cuff tears are one of the most common causes of shoulder malfunction and pain, which lead to a significant reduction in the quality of life. This present study investigated the effects of subacromial platelet-rich plasma injections [i.e. autologous conditioned plasma (ACP) injections] as compared to standard subacromial cortisone injection therapy in 50 patients with partial rotator cuff tears. METHODS: Before injection, and 6 weeks, 12 weeks and 6 months thereafter, the patients were assessed by the Constant-Murley score (CMS), the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), the simple shoulder test (SST) and a pain visual analogue scale (VAS). An MRI was also performed before and 6 months after injection. RESULTS: Both patient groups had statistically significant better shoulder score outcomes over time. ASES, SST and CMS outcomes after 12 versus 6 weeks were better in the ACP group as compared to the cortisone group. VAS, ASES and CMS outcomes after 12 weeks versus baseline in the ACP group were better as compared to the cortisone group. There was a statistically significant difference between ACP group and cortisone group 12 weeks after injection regarding VAS, ASES, SST and CMS in favour of the ACP group. The MRI showed an improvement in grade of tendinopathy in both groups, however, without statistically significant differences between the two groups. CONCLUSION: Compared with cortisone injections, ACP injections show earlier benefit as compared to cortisone injections although a statistically significant difference after 6 months could not be found. Therefore, subacromial ACP injections are a good alternative to subacromial cortisone injections, especially in patients with contraindication to cortisone. LEVEL OF EVIDENCE: Therapeutic study, Level III.
Authors: Chris Hyunchul Jo; Ji Eun Kim; Kang Sup Yoon; Ji Ho Lee; Seung Baik Kang; Jae Hyup Lee; Hyuk Soo Han; Seung Hwan Rhee; Sue Shin Journal: Am J Sports Med Date: 2011-07-07 Impact factor: 6.202
Authors: Patricia E Heisterbach; Atanas Todorov; Rudolf Flückiger; Christopher H Evans; Martin Majewski Journal: Knee Surg Sports Traumatol Arthrosc Date: 2011-11-29 Impact factor: 4.342
Authors: Lauren V Schnabel; Hussni O Mohammed; Brian J Miller; William G McDermott; May S Jacobson; Kelly S Santangelo; Lisa A Fortier Journal: J Orthop Res Date: 2007-02 Impact factor: 3.494
Authors: Scott A Rodeo; Demetris Delos; Riley J Williams; Ronald S Adler; Andrew Pearle; Russell F Warren Journal: Am J Sports Med Date: 2012-04-10 Impact factor: 6.202
Authors: Robert J de Vos; Adam Weir; Hans T M van Schie; Sita M A Bierma-Zeinstra; Jan A N Verhaar; Harrie Weinans; Johannes L Tol Journal: JAMA Date: 2010-01-13 Impact factor: 56.272
Authors: Chris Hyunchul Jo; Ji Sun Shin; Young Gil Lee; Won Hyoung Shin; Hyang Kim; Seung Yeon Lee; Kang Sup Yoon; Sue Shin Journal: Am J Sports Med Date: 2013-08-06 Impact factor: 6.202
Authors: J Freeland Ackley; Michael Kolosky; Danielle Gurin; Robert Hampton; Richard Masin; David Krahe Journal: Medicine (Baltimore) Date: 2019-07 Impact factor: 1.817
Authors: Sang Jun Kim; Seung Mi Yeo; Soo Jin Noh; Chul-Won Ha; Byung Chan Lee; Hyo Sun Lee; Sun Jeong Kim Journal: J Orthop Surg Res Date: 2019-12-02 Impact factor: 2.359